Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

{
  "publication_number": "US2026102446A1",
  "country": "US",
  "kind": "A1",
  "title": "Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer",
  "abstract": "The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.",
  "claims": [
    "1. A method of treating Ewing sarcoma, neuroblastoma, rhabdoid tumor, osteosarcoma, rhabdomyosarcoma, B-cell lymphoma (e.g., diffuse large B-cell lymphoma), non-small cell lung carcinoma, colorectal, melanoma, head and neck squamous carcinoma, hepatocellular carcinoma, gastric carcinoma, breast cancer (e.g., triple negative breast carcinoma), cutaneous T-cell lymphoma, or multiple myeloma by administering a therapeutically effective amount of an oncolytic virus. 2. The method of claim 1, wherein said oncolytic virus is a herpes simplex virus. 3. The method of claim 1, wherein said oncolytic virus is talimogene laherparepvec. 4. A method of treating B-cell lymphoma, colorectal cancer, head and neck squamous carcinoma, or breast cancer (e.g., triple negative breast carcinoma), by administering: (i) a therapeutically effective amount of an oncolytic virus; and (ii) a therapeutically effective amount of a checkpoint inhibitor. 5. The method according to claim 4, wherein said checkpoint inhibitor is a CTLA-4, PD-L1, or a PD-L1 blocker. 6. The method of claim 4, wherein said oncolytic virus is a herpes simplex virus. 7. The method of claim 6, wherein said herpes simplex virus is talimogene laherparepvec. 8 - 16. (canceled) 17. The method of claim 2, wherein said herpes simplex virus is talimogene laherparepvec. 18. The method of claim 5, wherein said oncolytic virus is a herpes simplex virus. 19. The method of claim 18, wherein said herpes simplex virus is talimogene laherparepvec."
  ],
  "cpc": [
    "A61K 35/763",
    "A61P 35/00",
    "A61P 35/04",
    "C07K 14/70596",
    "C07K 16/2818",
    "C07K 16/2827"
  ],
  "filing_date": "2025-07-31",
  "publication_date": "2026-04-16",
  "application_number": "US-202519287666-A"
}